Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.
|
30756358 |
2019 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Bucindolol is a beta-blocker whose unique pharmacologic properties provide greater benefit in HF patients with reduced ejection fraction (HFrEF) who have the beta<sub>1</sub>-adrenergic receptor (ADRB1) Arg389Arg genotype.
|
31042551 |
2019 |
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.
|
30756358 |
2019 |
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Bucindolol is a beta-blocker whose unique pharmacologic properties provide greater benefit in HF patients with reduced ejection fraction (HFrEF) who have the beta<sub>1</sub>-adrenergic receptor (ADRB1) Arg389Arg genotype.
|
31042551 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
β2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β1-adrenergic receptor autoantibodies in heart failure.
|
29746700 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GENETIC-AF is the first randomized trial of pharmacogenetic guided rhythm control, and will test the safety and efficacy of bucindolol compared with metoprolol succinate for the prevention of recurrent symptomatic AF/AFL in patients with HFrEF and an ADRB1 Arg389Arg genotype.(ClinicalTrials.govNCT01970501).
|
29754666 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results Subjects in each trial had less all-cause mortality with high- versus no/low-dose BB if they had ADRB1 Arg389Arg (BEST: hazard ratio [HR]=0.40, P=0.002; HF-ACTION: HR=0.45, P=0.005) but not Arg389Gly genotype (both P>0.2).
|
30354340 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of β1-AR was significantly decreased in the left ventricle tissue of HF rats by immunohistochemistry and immunofluorescence.
|
29247373 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The lack of cardiac β1-adrenergic receptors (β1-AR) negatively affects the regulation of both cardiac inotropy and lusitropy, leading, in the long term, to heart failure (HF).
|
29466489 |
2018 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The lack of cardiac β1-adrenergic receptors (β1-AR) negatively affects the regulation of both cardiac inotropy and lusitropy, leading, in the long term, to heart failure (HF).
|
29466489 |
2018 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
β2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β1-adrenergic receptor autoantibodies in heart failure.
|
29746700 |
2018 |
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results Subjects in each trial had less all-cause mortality with high- versus no/low-dose BB if they had ADRB1 Arg389Arg (BEST: hazard ratio [HR]=0.40, P=0.002; HF-ACTION: HR=0.45, P=0.005) but not Arg389Gly genotype (both P>0.2).
|
30354340 |
2018 |
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GENETIC-AF is the first randomized trial of pharmacogenetic guided rhythm control, and will test the safety and efficacy of bucindolol compared with metoprolol succinate for the prevention of recurrent symptomatic AF/AFL in patients with HFrEF and an ADRB1 Arg389Arg genotype.(ClinicalTrials.govNCT01970501).
|
29754666 |
2018 |
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of β1-AR was significantly decreased in the left ventricle tissue of HF rats by immunohistochemistry and immunofluorescence.
|
29247373 |
2018 |
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
By logistic regression analysis, high fasting plasma glucose, smoking, high triglyceride and the Gly/Gly polymorphism in Arg389Gly ADRB1 all emerged as independent risk factors for hypertension.
|
29549925 |
2018 |
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Among Shors, the following factors increased AH risk: female sex, age, hypercholesterolemia, hyperbetacholesterinemia, hypertriglyceridemia, obesity (including transabdominal obesity), glucose intolerance, and the DD ACE, CT MTHFR, and AA ADRB1 genotypes; among the non-indigenous population, the main factors were age, hypercholesterolemia, hyperbetacholesterinemia, hypoalfacholesterinemia, hypertriglyceridemia, obesity (including transabdominal obesity), and ID ACE genotype.
|
29027816 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Let-7a regulates β1-AR expression and forms a negative feedback loop with β1-AR signaling pathway in ischemic heart failure.
|
28060734 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
More consistent to mammalians, adult zebrafish developed significant heart failure in concert with β1-AR downregulation, and GRK2 and brain natriuretic peptide (BNP) upregulation in response to prolonged, 14d ISO-stimulation.
|
28554511 |
2017 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
More consistent to mammalians, adult zebrafish developed significant heart failure in concert with β1-AR downregulation, and GRK2 and brain natriuretic peptide (BNP) upregulation in response to prolonged, 14d ISO-stimulation.
|
28554511 |
2017 |
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Let-7a regulates β1-AR expression and forms a negative feedback loop with β1-AR signaling pathway in ischemic heart failure.
|
28060734 |
2017 |
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A new sight for detecting the ADRB1 gene mutation to guide a therapeutic regimen for hypertension based on a CeO<sub>2</sub>-doped nanoprobe.
|
27829563 |
2017 |
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The β1‑adrenergic receptor (AR) is the primary β‑AR subtype in the heart and is the target of metoprolol (Met), which is commonly used to treat angina and hypertension.
|
28000860 |
2017 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Data from our study suggest that the β adrenoreceptor Gly 49 allele of the β1 -adrenergic receptor Ser(49) Gly polymorphisms may increase the risk of ICD shock in patients with heart failure, independent of beta-blocker dosage.
|
27027728 |
2016 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
|
26879662 |
2016 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings that BAG3 is localized at the sarcolemma and t-tubules while modulating myocyte contraction and action potential duration through specific interaction with the β1-adrenergic receptor and L-type Ca(2+) channel provide novel insight into the role of BAG3 in cardiomyopathies and increased arrhythmia risks in heart failure.
|
26796036 |
2016 |